CCT2

Across TCGA pan-cancer cohorts, CCT2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CCT2 data layer compared with 28 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CCT2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CCT2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and COAD show a favorable association.

LUAD, LSCC, and COAD are the cancer types where CCT2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	All	0.639	0.918	.001	28	view →
LSCC	DFS	Quartile	II,III,IV	0.766	0.187	.024	7	view →
COAD	DFS	Median	III,IV	1.000	0.846	.049	6	view →
PDAC	DFS	Median	All	0.348	0.227	.034	3	view →
HNSC	OS	Median	III,IV	0.933	0.774	.039	3	view →
GBM	DFS	Quartile	All	0.158	0.423	.049	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CCT2–LUAD (OS)

Open the LUAD breakdown →